Martin Zeltner

Title: Martin Zeltner: Innovator in Bioconjugates and Cancer Therapy

Introduction

Martin Zeltner is a notable inventor based in Feuerthalen, Switzerland. He has made significant contributions to the field of bioconjugates, particularly in the context of cancer therapy and diagnosis. His innovative work focuses on the development of bioconjugates that combine antibodies with functionalized magnetic nanoparticles.

Latest Patents

Zeltner holds a patent for "Bioconjugates of antibodies and functionalized magnetic nanoparticles." This invention relates to antibodies that are useful in therapeutic and diagnostic applications. The patent specifically discloses bioconjugates that comprise one or more antibodies bound to functionalized magnetic nanoparticles. These bioconjugates are particularly useful in cancer therapy, especially for the removal of circulating tumor cells. The invention also pertains to specific functionalized magnetic nanoparticles and the manufacturing processes for these bioconjugates.

Career Highlights

Throughout his career, Martin Zeltner has worked with prestigious institutions, including the University of Zurich and ETH Zurich. His work in these institutions has allowed him to advance his research and contribute to the scientific community significantly.

Collaborations

Zeltner has collaborated with notable colleagues such as Antoine Florent Herzog and Wendelin Jan Stark. These collaborations have further enriched his research and innovation in the field of bioconjugates.

Conclusion

Martin Zeltner's contributions to the field of bioconjugates and cancer therapy highlight his role as an innovative inventor. His work continues to impact the medical field, particularly in the diagnosis and treatment of cancer.